New peptide-based drugs for the treatment of neuropathic pain (2010–2012)
Chronic pain affects 1 in 5 Australians and neuropathic pain is among the most severe forms of chronic pain. Peptides from cone snail venoms have attracted recent attention as potential therapeutic agents for the treatment of neuropathic pain. Unfortunately, these peptides suffer from the disadvantage of short biological half-lives and poor activity when taken orally. We have developed a new approach to solve these problems that we will apply to develop new drugs for the treatment of pain.